首页|接骨丸在锁骨中段骨折保守治疗中应用的临床疗效及安全性

接骨丸在锁骨中段骨折保守治疗中应用的临床疗效及安全性

扫码查看
目的 评价接骨丸在锁骨中段骨折保守治疗中应用的临床疗效及安全性.方法 54 例锁骨中段骨折患者随机分为对照组及试验组,各27 例;2 组患者均接受保守治疗,对照组给予接骨七厘片1.5 g,bid,口服;试验组给予接骨丸3.0 g,bid,口服.比较2 组患者治疗前后血清骨钙素(BGP)、总Ⅰ型胶原氨基端延长肽(TPINP)、碱性磷酸酶(ALP)水平、治疗有效率及不良反应的发生率.结果 治疗后,与对照组比较,试验组患者血清BGP、TPINP 及ALP 水平较高( P< 0.05).试验组的治疗有效率(96.29%)显著高于对照组(77.78%)( P< 0.05).2组患者不良反应发生率无明显差异.结论 接骨丸能够显著提高锁骨中段骨折患者的血清BGP、TPINP及ALP水平,促进骨折愈合,临床疗效及安全性较高.
Clinical curative effect and safety of application of Jiegu pill in the conservative treatment of patients with middle clavicle fracture
Objective To evaluate the clinical curative effect and safety of application of Jiegu pill in the conservative treatment of patients with middle clavicle fracture.Methods Fifty-four cases of patients with middle clavicle fracture were randomly divided into the control group and treatment group,27 cases in each group.Two groups of patients were treated with conservative treatment,the control group was given Jiegu Qili Pian1.5g,bid,oral; the experimental group was treated with Jiegu pill 3.0g,bid,oral.Before and after treatment,compared between the two groups of patients with serum Osteocalcin(BGP),total type I collagen amino terminal peptide(TPINP),alkaline phosphatase(ALP)levels,efficiency of treatment and incidence of adverse reactions.Results After treatment,compared with the control group,the serum levels of BGP、TPINP and ALP were higher in the experimental group(P<0.05).The treatment efficiency of the experimental group(96.29%)was significantly higher than that of the control group(77.78%)(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups.Conclusion The Jiegu pill can significantly improve the serum levels of BGP、TPINP and ALP in patients with middle clavicle fracture,promote fracture healing,the clinical efficacy and safety were high.

jiegu pillmiddle clavicle fractureconservative treatmentclinical efficacysafety

蒋焕泽、钟甫华

展开 >

仙居县中医院 骨伤科,浙江 台州 317300

浙江省立同德医院骨科,浙江 杭州 310012

接骨丸 锁骨中段骨折 保守治疗 临床疗效 安全性

2017

中国生化药物杂志
南京生物化学制药研究所,全国生化制药情报中心站,中国生化制药工业协会,中国药品生物制品检定所

中国生化药物杂志

ISSN:1005-1678
年,卷(期):2017.(4)
  • 6